Cytokeratin 20 Positive Circulating Tumor Cells Are a Marker for Response After Neoadjuvant Chemoradiation but Not for Prognosis in Patients with Rectal Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2015 Dec 18

PMID 26674974

Citations 19

Authors

Sebastian Hinz

Christian Roder

Jurgen Tepel

Alexander Hendricks

Clemens Schafmayer

Thomas Becker

Holger Kalthoff

Affiliations

Soon will be listed here.

Abstract

Background: Several studies have shown, that circulating tumor cells (CTC) have a negative prognostic value in colorectal cancer patients. Aim of this study was to evaluate the role of CTC in specifically rectal cancer patients regarding the influence on overall survival and to elucidate the impact of CTC in predicting response after chemoradiation (RCTX).

Methods: In this prospective monocentric study 267 patients with rectal cancer were included. Patients with locally advanced tumors were treated with RCTX followed by surgery. The primary endpoints were: Evaluation of CTC at the time of surgery and correlation with main tumor characteristics, response to neoadjuvant RCTX and overall survival (OS). CTC were detected in the blood using CK20 RT-PCR.

Results: Sixty-three patients were treated with neoadjuvant RCTX. In 46.8% of the patients receiving neoadjuvant RCTX CTC were detected, which was significantly higher than in the group without RCTX (p=0.002). Histopathologic regression after RCTX was evident in 27.8% of the patients. In the subgroup of responders after RCTX we found CTC at a significantly lower rate than in non-responders (p=0.03). No significant association was found between CTC detection and tumor characteristics and OS. The OS was significantly improved for responders compared to non-responders (p=0.007).

Conclusions: Responders after neoadjuvant RCTX had a lower incidence of CTC compared to non-responders, which might be a result of effective systemic and local treatment prior to surgery. Interestingly, detection of CTC did not correlate with tumor stage and OS, which is in contrast to previous reports of patients with colon cancer.

Citing Articles

Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence.

Tsai K, Huang P, Chu P, Nguyen T, Hung H, Hsieh C Cancers (Basel). 2024; 16(13).

PMID: 39001379 PMC: 11240518. DOI: 10.3390/cancers16132316.

The Crying Need for a Better Response Assessment in Rectal Cancer.

Amintas S, Giraud N, Fernandez B, Dupin C, Denost Q, Garant A Curr Treat Options Oncol. 2023; 24(11):1507-1523.

PMID: 37702885 PMC: 10643426. DOI: 10.1007/s11864-023-01125-9.

Circulating Tumour Cell Associated MicroRNA Profiles Change during Chemoradiation and Are Predictive of Response in Locally Advanced Rectal Cancer.

Lim S, Chua W, Ng W, Ip E, Marques T, Tran N Cancers (Basel). 2023; 15(16).

PMID: 37627212 PMC: 10452825. DOI: 10.3390/cancers15164184.

Metastasis risk stratification and response prediction through dynamic viable circulating tumor cell counts for rectal cancer in a neoadjuvant setting.

Liu W, Zhang W, Tang Y, Chen S, Li N, Lei J Cancer Med. 2023; 12(10):11438-11450.

PMID: 37014817 PMC: 10242869. DOI: 10.1002/cam4.5860.

Clinical Utility of Circulating Tumor Cells for Predicting Major Histopathological Response after Neoadjuvant Chemoradiotherapy in Patients with Esophageal Cancer.

Gao X, Leow O, Chiu C, Hou M, Hsieh J, Chao Y J Pers Med. 2022; 12(9).

PMID: 36143225 PMC: 9502866. DOI: 10.3390/jpm12091440.

References

Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C . Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 30(16):1926-33. DOI: 10.1200/JCO.2011.40.1836. View

Nesteruk D, Rutkowski A, Fabisiewicz S, Pawlak J, Siedlecki J, Fabisiewicz A . Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy: prospectively collected material data. Biomed Res Int. 2014; 2014:712827. PMC: 4070579. DOI: 10.1155/2014/712827. View

Flatmark K, Borgen E, Nesland J, Rasmussen H, Johannessen H, Bukholm I . Disseminated tumour cells as a prognostic biomarker in colorectal cancer. Br J Cancer. 2011; 104(9):1434-9. PMC: 3101945. DOI: 10.1038/bjc.2011.97. View

He Y, Vant Veer L, Mikolajewska-Hanclich I, van Velthuysen M, Zeestraten E, Nagtegaal I . PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res. 2009; 15(22):6956-62. DOI: 10.1158/1078-0432.CCR-09-1165. View

Roth A, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D . Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2009; 28(3):466-74. DOI: 10.1200/JCO.2009.23.3452. View

Soeth E, Roder C, Juhl H, Kruger U, Kremer B, Kalthoff H . The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Int J Cancer. 1996; 69(4):278-82. DOI: 10.1002/(SICI)1097-0215(19960822)69:4<278::AID-IJC7>3.0.CO;2-U. View

van de Stolpe A . On the origin and destination of cancer stem cells: a conceptual evaluation. Am J Cancer Res. 2013; 3(1):107-16. PMC: 3555199. View

Meng X, Huang Z, Wang R, Yu J . Prediction of response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Biosci Trends. 2014; 8(1):11-23. DOI: 10.5582/bst.8.11. View

Lordick F, Ott K, Krause B, Weber W, Becker K, Stein H . PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8(9):797-805. DOI: 10.1016/S1470-2045(07)70244-9. View

10.

Riethdorf S, Wikman H, Pantel K . Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008; 123(9):1991-2006. DOI: 10.1002/ijc.23825. View

11.

Zitt M, Zitt M, Muller H, Dinnewitzer A, Schwendinger V, Goebel G . Disseminated tumor cells in peripheral blood: a novel marker for therapy response in locally advanced rectal cancer patients undergoing preoperative chemoradiation. Dis Colon Rectum. 2006; 49(10):1484-91. DOI: 10.1007/s10350-006-0673-4. View

12.

Karapetis C, Khambata-Ford S, Jonker D, OCallaghan C, Tu D, Tebbutt N . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-65. DOI: 10.1056/NEJMoa0804385. View

13.

Hinz S, Bockhorst J, Roder C, Egberts J, Schafmayer C, Kuchler T . Disseminated tumor cells in the bone marrow negatively influence survival after resection of colorectal liver metastases. Ann Surg Oncol. 2012; 19(8):2539-46. DOI: 10.1245/s10434-012-2291-9. View

14.

Akiyoshi T, Kobunai T, Watanabe T . Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today. 2012; 42(8):713-9. DOI: 10.1007/s00595-012-0223-8. View

15.

Welinder C, Jansson B, Lindell G, Wenner J . Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer. Cancer Lett. 2014; 358(1):43-6. DOI: 10.1016/j.canlet.2014.12.024. View

16.

Soeth E, Vogel I, Roder C, Juhl H, Marxsen J, Kruger U . Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res. 1997; 57(15):3106-10. View

17.

Magni E, Botteri E, Ravenda P, Cassatella M, Bertani E, Chiappa A . Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. Int J Colorectal Dis. 2014; 29(9):1053-9. DOI: 10.1007/s00384-014-1958-z. View

18.

Raimondi C, Gradilone A, Naso G, Cortesi E, Gazzaniga P . Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo. Onco Targets Ther. 2014; 7:619-25. PMC: 4000244. DOI: 10.2147/OTT.S46200. View

19.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

20.

Hinz S, Tepel J, Roder C, Kalthoff H, Becker T . Profile of serum factors and disseminated tumor cells before and after radiofrequency ablation compared to resection of colorectal liver metastases - a pilot study. Anticancer Res. 2015; 35(5):2961-7. View